ABT (Abbott Laboratories)
Insider Trading Activity
Every open-market purchase and sale reported by ABT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Louis H. Morrone | EXECUTIVE VICE PRESIDENT | MIXED | — | — |
| 2026-07-01 | Patricia Paola Gonzalez | Director | A | — | — |
| 2026-07-01 | Nita Ahuja | Director | A | — | — |
| 2026-07-01 | Michael F Roman | Director | A | — | — |
| 2026-07-01 | Kevin T Conroy | Director | A | — | — |
| 2026-07-01 | Louis H. Morrone | EXECUTIVE VICE PRESIDENT | F | — | — |
| 2026-07-01 | John G Stratton | Director | A | — | — |
| 2026-06-29 | Elizabeth C. Cushman | EVP, GC AND SECRETARY | F | — | — |
| 2026-06-18 | John G Stratton | Director | Buy | — | — |
| 2026-04-29 | Mary K Moreland | EXECUTIVE VICE PRESIDENT | I | — | — |
| 2026-04-28 | Nita Ahuja | Director | A | — | — |
| 2026-04-28 | Claire Babineaux-Fontenot | Director | A | — | — |
| 2026-04-28 | Sally E. Blount | Director | A | — | — |
| 2026-04-28 | Patricia Paola Gonzalez | Director | A | — | — |
| 2026-04-28 | Michelle Kumbier | Director | A | — | — |
| 2026-04-28 | Darren W McDew | Director | A | — | — |
| 2026-04-28 | Nancy McKinstry | Director | A | — | — |
| 2026-04-28 | Michael O'Grady | Director | A | — | — |
| 2026-04-28 | Michael F Roman | Director | A | — | — |
| 2026-04-28 | DANIEL J STARKS | Director | MIXED | — | — |
| 2026-04-28 | John G Stratton | Director | A | — | — |
| 2026-04-28 | Kevin T Conroy | Director | A | — | — |
| 2026-04-27 | Philip P Boudreau | EVP AND CFO | MIXED | — | — |
| 2026-04-02 | Nita Ahuja | Director | A | — | — |
| 2026-04-02 | Robert J Alpern | Director | A | — | — |
| 2026-04-02 | Patricia Paola Gonzalez | Director | A | — | — |
| 2026-04-02 | Michael F Roman | Director | A | — | — |
| 2026-04-02 | John G Stratton | Director | A | — | — |
| 2026-03-25 | JACOB A ORVILLE | Senior Vice President | A | — | — |
| 2026-03-03 | Philip P Boudreau | EVP AND CFO | F | — | — |
| 2026-03-03 | Elizabeth C. Cushman | EVP, GC AND SECRETARY | MIXED | — | — |
| 2026-03-03 | Lisa D Earnhardt | EVP AND GROUP PRESIDENT | F | — | — |
| 2026-03-03 | Robert B Ford | CHAIRMAN AND CEO | F | — | — |
| 2026-03-03 | JOHN A. JR. MCCOY | VICE PRESIDENT AND CONTROLLER | MIXED | — | — |
| 2026-03-03 | Mary K Moreland | EXECUTIVE VICE PRESIDENT | MIXED | — | — |
| 2026-03-03 | Louis H. Morrone | EXECUTIVE VICE PRESIDENT | MIXED | — | — |
| 2026-03-03 | Daniel Gesua Sive Salvadori | EVP AND GROUP PRESIDENT | MIXED | — | — |
| 2026-03-03 | Christopher J Scoggins | EXECUTIVE VICE PRESIDENT | F | — | — |
| 2026-03-03 | Eric Shroff | Senior Vice President | MIXED | — | — |
| 2026-02-26 | Philip P Boudreau | EVP AND CFO | A | — | — |
| 2026-02-26 | Elizabeth C. Cushman | EVP, GC AND SECRETARY | A | — | — |
| 2026-02-26 | Lisa D Earnhardt | EVP AND GROUP PRESIDENT | A | — | — |
| 2026-02-26 | Robert B Ford | CHAIRMAN AND CEO | A | — | — |
| 2026-02-26 | JOHN A. JR. MCCOY | VICE PRESIDENT AND CONTROLLER | A | — | — |
| 2026-02-26 | Mary K Moreland | EXECUTIVE VICE PRESIDENT | A | — | — |
| 2026-02-26 | Louis H. Morrone | EXECUTIVE VICE PRESIDENT | A | — | — |
| 2026-02-26 | Daniel Gesua Sive Salvadori | EVP AND GROUP PRESIDENT | A | — | — |
| 2026-02-26 | Christopher J Scoggins | EXECUTIVE VICE PRESIDENT | A | — | — |
| 2026-02-26 | Eric Shroff | Senior Vice President | A | — | — |
| 2026-02-06 | DANIEL J STARKS | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 6,751,361 | — |
| — | EXECUTIVE CHAIRMAN | 3,128,641 | — |
| — | Pres., Cardiovas. & Neuromod. | 629,294 | — |
| — | Executive Vice President | 580,807 | — |
| — | CHAIRMAN AND CEO | 522,664 | — |
| — | Executive Vice President | 514,682 | — |
| — | Senior Vice President | 493,961 | — |
| — | Executive Vice President | 354,517 | — |
| — | EXECUTIVE VICE PRESIDENT | 339,443 | — |
| — | Executive Vice President | 299,115 | — |
| — | Executive Vice President | 248,776 | — |
| — | Executive Vice President | 229,617 | — |
| — | Executive Vice President | 227,633 | — |
| — | EXECUTIVE VICE PRESIDENT | 221,938 | — |
| — | EXECUTIVE VICE PRESIDENT, GC | 191,899 | — |
| — | Senior Vice President | 172,123 | — |
| — | Executive Vice President | 168,366 | — |
| — | Senior Vice President | 155,134 | — |
| — | EVP AND GROUP PRESIDENT | 147,262 | — |
| — | Vice President | 141,609 | — |
| — | Senior Vice President | 136,138 | — |
| — | Executive Vice President | 134,575 | — |
| — | Director | 133,737 | — |
| — | Senior Vice President | 132,249 | — |
| — | Executive Vice President | 129,064 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ABT quote page; the site-wide leaderboard is on the insider transactions hub.